Attentional biases to body shape images in adolescents with anorexia nervosa: an exploratory eye-tracking study.

Body image distortion (BID) plays an important role in the etiology and maintenance of anorexia nervosa (AN). Previous studies of BID in AN showed small biases in visual scanning behavior (VSB) towards images of body shapes. The aim of this study is to investigate biases in VSB when body shape images compete with images with a different theme (social interactions) for subjects׳ attention.

Astroglial structures in the zebrafish brain.

To understand components shaping the neuronal environment we studied the astroglial cells in the zebrafish brain using immunocytochemistry for structural and junctional markers, electron microscopy including freeze fracturing, and probed for the water channel protein aquaporin-4. Glial fibrillary acidic protein (GFAP) and glutamine synthetase (GS) showed largely overlapping immunoreactivity: GFAP in the main glial processes and GS in main processes and smaller branches. Claudin-3 immunoreactivity was spread in astroglial cells along their major processes.

A novel microsurgical nerve implantation technique preserving outer nerve layers.

A novel epineural tube implantation paradigm in the adult rat was designed for the analysis of regulatory cell interactions in peripheral nerves and for the development of therapeutic implants. The aim was to allow the integration of synthetic regenerative structures and cells into the nerve interior while preserving an outer nerve tissue layer with a supportive vasculature. The microsurgical technique allowed us to remove the interfascicular epineurium, leaving behind an epineural tube with an intact tissue wall of about 0.

Calculated bioavailable testosterone levels and depression in middle-aged men.

Background: The association between circulating total testosterone (TT) levels and depressive symptoms remains unclear. We sought to determine the relationship between physiologically active bioavailable testosterone (BT) and depressive symptoms in middle-aged men with and without major depressive disorder (MDD).

Methods: We assessed and compared calculated BT levels in two groups of middle-aged men (40-65 years): untreated subjects meeting DSM-IV-TR-defined criteria for a major depressive episode as part of major depressive disorder (N=44) and a matched non-depressed control group (N=50).

Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale.

Background: Symptomatic remission is the optimal outcome in depression. A brief, validated tool for symptom measurement that can indicate when remission has occurred in mental health and primary care settings is unavailable. We evaluated a 7-item abbreviated version (HAMD-7) of the 17-item Hamilton Depression Rating Scale (HAMD-17) in a randomized controlled clinical trial of patients with major depressive disorder being cared for in primary care settings.

Is the cerebellum relevant in the circuitry of neuropsychiatric disorders?

Contemporary mechanistic models of several psychiatric disorders propose abnormalities in the structure and function of distinct neural networks. The cerebellum has both anatomic and functional connections to the prefrontal cortex, the subcortical limbic structures and monoamine-producing brainstem nuclei. Conspicuously, however, the cerebellum has been underemphasized in neuropsychiatric research.

A naturalistic visual scanning approach to assess selective attention in major depressive disorder.

Cognitive biases in information processing play an important role in the etiology and maintenance of emotional disorders. A new methodology to measure attentional biases is presented; this approach encourages subjects to scan and re-scan images with different thematic content, while the pattern of their attentional deployment is continuously monitored by an eye-tracking system. Measures of attentional bias are the total fixation time and the average glance duration on images belonging to a particular theme.

Cocaine, HIV, and their cardiovascular effects: is there a role for ACE-inhibitor therapy?

Cocaine abuse and HIV disease each have potentially adverse effects upon the heart and cardiovascular system which may be exacerbated when these risk factors are combined. The development of a safe and effective agent to treat both cocaine addiction and its cardiovascular sequelae, that is well-tolerated by HIV patients, would thus be of considerable clinical utility. In this article we discuss the rationale for the investigation of angiotensin converting enzyme (ACE) inhibitors, commonly used to treat hypertension, for treatment in cocaine-abusing populations, based on their potential to reduce cocaine use by modulating levels of dopamine and corticotropin releasing factor in the brain, and on their ability to reverse cardiovascular and platelet abnormalities.

The reduction in alcohol intake in rats by isoproterenol is attenuated by indomethacin but not enalapril: relationship to blood glucose levels.

Many adrenergic agonists including isoproterenol, a beta1,2-adrenergic agonist, reduce alcohol consumption, but the mechanism of this effect is not known. Adrenergic agonists have a variety of effects, among which are their ability to raise both angiotensin (ANG) II activity and plasma glucose levels. Previous research has shown that ANG II and enhanced glucose levels are accompanied by reductions in alcohol intake.

The reduction in alcohol intake by the 5-HT1A agonist 8-OH DPAT and its attenuation by the alpha 2 adrenergic antagonist idazoxan correlates with blood glucose levels.

Serotonergic agents in general and the 5-HT1A agonist 8-OH DPAT in particular, reduce alcohol intake in rats and primates but the mechanism of this effect is not known. Previous studies have shown a correlation between alcohol consumption and the propensity to consume sweet substances. Indeed, certain biochemical events accompanying glucose utilization have been proposed as satiety signals in the control of feeding.

Glucose and the insulin-releasing drug tolbutamide attenuate the effects of morphine and angiotensin on alcohol consumption.

Animals studies have shown that insulin injections reduce alcohol intake, implicating glucoregulatory processes in alcohol consumption. Angiotensin (ANG) II reduces alcohol intake and promotes glycogen breakdown in the liver but no studies have assessed the role of glucoregulatory processes in ANG II's effect. Similarly, glucose injections attenuate the analgesic and cognitive effects of opiates, yet no studies have assessed the effect of glucose on the well-documented ability of opiates to enhance alcohol consumption.

Characterization of the decline in alcohol consumption by aminopeptidase inhibition.

Bestatin, an aminopeptidase inhibitor, prolongs the action of angiotensin and enkephalin. Previous studies have shown that bestatin can reduce alcohol intake in heterogeneous as well as genetically selected alcohol preferring 'P' rats, but more detailed studies of the characteristics of this effect have not yet been done. In experiment 1, daily injections of 10, 20 or 40 mg/kg bestatin for 12 days produced a uniform reduction in alcohol intake (approximately 40%) which did not recover following suspension of bestatin, but did recover following a 7 day period of morphine-stimulated alcohol drinking.

Effect of bestatin, an aminopeptidase inhibitor, on alcohol intake in alcohol-preferring P rats.

Bestatin is an aminopeptidase and enkephalinase inhibitor that elevates the levels of angiotensin II and angiotensin III. Although it has been used for years in the treatment of various forms of cancer, its application as an antialcohol drug has not been explored, despite its ability to stimulate angiotensin activity. The present study assesses the ability of bestatin to reduce chronic alcohol consumption in the genetically selected high alcohol-consuming P rats.

Neurotensin attenuates the reduction in alcohol drinking produced by angiotensin II.

Neurotensin enhances some of the behavioral effects of alcohol including motor impairment, narcosis, hypothermia and also interacts with some of the physiological actions of angiotensin (ANG) II including aldosterone release and increased blood pressure. ANG II injections also produce a dose-dependent antagonist reversible reduction in alcohol drinking. The present study is the first to examine the interaction between neurotensin and angiotensin in the behavioral context of oral alcohol self-administration.

Intracerebroventricularly infused angiotensin II or III do not alter voluntary alcohol intake in rats.

Subcutaneous injections of angiotensin (ANG) II or III in the periphery reduce alcohol intake and raise water intake. These peptides do not cross the blood-brain barrier and cannot reach the angiotensin receptor-rich sites surrounding the lateral and third ventricles. To examine the effect on alcohol intake of ANG II and III at these ventricular sites, groups of rats were first trained to drink alcohol using a limited access procedure, then surgically prepared with chronic indwelling lateral or third ventricular cannulae, and then reoffered daily 40-min access to alcohol.

Increased alcohol consumption in weight-reduced rats is modulated by the renin-angiotensin system.

Weight reduction and food restriction increase the self-administration of alcohol and other drugs of abuse, but the underlying physiological mechanisms have not been identified. Because weight reduction alters angiotensin (ANG) II activity, and ANG II is known to modulate alcohol intake, ANG II may play a role in the enhanced alcohol consumption of food-deprived weight-reduced rats and in the drop in alcohol intake when these rats are refed. Two groups of rats were reduced to and maintained at 80% of their free feeding weights and offered daily 40 min access to a 6% (w/v) alcohol solution and water.

The reduction in alcohol intake produced by enalapril is not attenuated by centrally administered angiotensin inhibitors.

Angiotensin-converting enzyme (ACE) inhibitors, which prevent the conversion of angiotensin I to angiotensin II, reduce alcohol intake when injected peripherally. The mechanism by which ACE inhibitors produce this effect on alcohol intake is unknown. A rise in the biosynthesis of angiotensin II in the periphery is known to reduce alcohol intake.

Adrenalectomy does not modify the suppressive effect of angiotensin II on voluntary ethanol drinking in rats.

Enhancement of activity in the renin-angiotensin system reduces voluntary ethanol consumption in rats. Because angiotensin II, which is a major bioactive component of the renin-angiotensin system, stimulates the release of aldosterone, aldosterone may play a role in the reduction of ethanol intake by angiotensin II. The present study examined ethanol drinking in a group of rats that was bilaterally adrenalectomized and incapable of producing aldosterone, and in a sham group that underwent similar surgery except that the adrenal glands were left intact.

The reduction in alcohol drinking by peripherally injected angiotensin II is selectively mediated by the AT1 receptor subtype.

We investigated which of the two angiotensin (ANG) receptor subtypes mediates the reduction in alcohol intake produced by peripheral injections of ANG II. Adult male Wistar rats were trained to self-administer alcohol (6% w/v) using a procedure that, by limiting access to a brief daily availability period (40 min), fosters a bout pattern of alcohol drinking and a pharmacodynamic effect. Water was continuously available.

Reduction of voluntary alcohol consumption in the rat by transplantation of hypothalamic grafts.

Stimulation of the peripheral renin-angiotensin system has been shown previously to decrease the voluntary intake of ethanol in the rat. The existence of a separate brain renin-angiotensin system, independent from that of the periphery, has been widely demonstrated. The brain renin-angiotensin system plays an important role in the regulation of water and electrolyte balance and neuroendocrine function.

Bradykinin suppresses alcohol intake and plays a role in the suppression produced by an ACE inhibitor.

The possible role of the endogenous kinins in the control of alcohol intake was assessed in two experiments. In Experiment 1, naive rats, maintained on ad lib food and water, were given daily 40-min access to a 6% (w/v) alcohol solution and water. Daily intraperitoneal (IP) injections of captopril (20 mg/kg) significantly reduced alcohol intake, while pretreatment with subcutaneous (SC) injections of the bradykinin antagonist [D-Phe7]-bradykinin (100-300 micrograms/kg) attenuated the suppressive effect of captopril on alcohol intake.

Captopril and hydrochlorothiazide (Capozide) combine to enhance the reduction in voluntary alcohol intake in rats.

The effect of Capozide, the combination of captopril with a hydrochlorothiazide diuretic, on voluntary alcohol intake was assessed in two experiments. In experiment 1 naive rats who were maintained on ad libitum food and water were given daily 40-min access to a 6% (w/v) alcohol solution and water. Daily intraperitoneal injections of captopril (10 mg/kg) reduced alcohol intake, but the combination of captopril (5 and 10 mg/kg) and hydrochlorothiazide (2.

Reduction of ethanol intake by aerosol inhalation of a beta-adrenergic agonist: new route--new treatment approach?

The quick, convenient, unobtrusive administration of a low dose of a drug that effectively reduces alcohol intake could be a useful adjunct to any program that aims to treat alcohol abuse. This study evaluates the ability of isoproterenol, a drug that has previously been shown to reduce ethanol intake, to exercise this action when administered as a metered aerosol mist. Rats were trained to self-administer ethanol using a procedure that limits access to a brief daily availability period.

Bestatin, an aminopeptidase B inhibitor, selectively reduces alcohol intake in rats.

Extensive research has shown that manipulations that augment activity in the renin-angiotensin system can reduce alcohol intake. Inhibition of aminopeptidase B and M can prolong the action of angiotensin (ANG) II and ANG III by preventing their degradation. This study assessed the ability of bestatin, an aminopeptidase B and M inhibitor, to decrease alcohol intake.

Angiotensin II mediates a conditioned taste aversion in water-replete rats.

Many compounds that exert an influence on behavioral processes will, under the unique conditions of the conditioned taste aversion (CTA) procedure, cause animals to avoid consuming an otherwise preferred fluid. While angiotensin II (ANG II) is a peptide with a number of behavioral and physiological actions, previous research did not support its role as an agent capable of inducing a CTA. Those studies used fluid deprivation to induce fluid intake and only a single conditioning trial.